DCT and neoplasm: This effect appears to result in a better CD8+ T-cell tumor response, as indicated by a greater frequency and number of IT CD8+ T cells specific for the melanoma tumor antigen tyrosinase-related protein-2 (TRP-2) (TRP-2/Tet+CD8+ T cells) (Fig. 4J–L) and higher expression of TNF-α, IFN-γ, and granzyme B (GzmB) in TRP-2/Tet+CD8+ T cells (Fig. 4J, M–O).